Compass Therapeutics’ (CMPX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $32.00 target price on the stock.

Several other equities research analysts have also commented on CMPX. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group boosted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Finally, Piper Sandler initiated coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.38.

Compass Therapeutics Price Performance

CMPX stock opened at $2.97 on Tuesday. The firm has a 50-day moving average of $2.49 and a 200 day moving average of $1.92. The company has a market cap of $408.64 million, a P/E ratio of -8.03 and a beta of 1.17. Compass Therapeutics has a 1 year low of $0.76 and a 1 year high of $4.08.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently modified their holdings of the business. SG Americas Securities LLC lifted its stake in Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares during the period. Rovin Capital UT ADV purchased a new position in shares of Compass Therapeutics during the third quarter valued at approximately $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics during the third quarter valued at approximately $30,000. The Manufacturers Life Insurance Company purchased a new stake in Compass Therapeutics in the third quarter worth approximately $79,000. Finally, XTX Topco Ltd bought a new stake in Compass Therapeutics in the 3rd quarter worth approximately $37,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.